Disorders of Movement

Disorders of Movement : Clinical, Pharmacological and Physiological Aspects

By (author)  , By (author) 

List price: US$178.00

Currently unavailable

Add to wishlist

AbeBooks may have this title (opens in new window).

Try AbeBooks

Description

Professor David Marsden is a world authority on movement disorders. His past and present students and co-workers have produced this compilation of a wealth of knowledge, covering a wide range of motor disturbances, as a tribute to him.
show more

Product details

  • Hardback | 512 pages
  • Academic Press Inc
  • San Diego, United States
  • English
  • 012569685X
  • 9780125696852

Table of contents

Part 1 Parkinson's disease: is there a Parkinson's disease?; organization of the basal ganglia; the pathology of Parkinson's disease; the pathophysiology of Parkinson's disease; models of cognitive dysfunction in Parkinson's disease; biochemistry of neurotransmitters in Parkinson's disease; the neurochemistry of Parkinson's disease as revealed by PET scanning; sleep and Parkinson's disease; different therapeutic approaches to complicated Parkinson's disease; the anti-Parkinsonian effects of transdermal (+)-PHONO -MPTP and its relevance to Parkinson's disease; the role of dopamine in the selectivity of the neurotoxin MPTP for nigrostriatal dopamine neurons; effects of dopamine D-1 and D-2 receptor stimulation in MPTP monkeys; chronic infusions of dopamine agonists in animals; delivery of (+)-4-propyl-9-hydroxy-naphthoxazine [(+)-PHNO] by a novel orally administered osmotic tablet - behavioural effect in animal models of Parkinson's disease; studies towards neural transplantation in Parkinson's disease - dystonia - the pathophysiology of dystonia; pathophysiology of cranial dystonia - a review; positron emission tomographic investigations of dystonia; blepharospasm - clinical aspects of their therapeutic considerations; the treatment of spasmodic torticollis; surgical treatment of spasmodic torticollis; drug treatment of dystonia; dopa-responsive dystonia - 20 years into the levodopa era; the clinical use of botulinium toxin; dystonia; where next?. Part 2 Neuroleptic-induced movement disorders: neuroleptic-induced movement disorders; the consequences of chronic exposure to neuroleptics in the rat; experimental models of acute dystonia. Part 3 Other movement disorders: degenerative ataxic disorders; the physiology of myoclonus in man; experimental models of myoclonus; the bio-chemistry of Huntington's chorea; classification of tremor; orthostatic tremor; long-latency reflexes; cortical stimulation in man. Part 4 Concluding Remarks: movement disorders; the problem of definition.
show more